Reply to: Comment on: "Adherence to hydroxyurea and clinical outcomes among children with sickle cell anemia"

被引：0
|
作者：
Reeves, Sarah L. [1 ,2 ,6 ]
Dombkowski, Kevin J. [1 ]
Peng, Hannah K. [1 ]
Phan, Hanna [3 ]
Kolenic, Giselle [4 ]
Creary, Susan E. [5 ]
Madden, Brian [1 ]
Lisabeth, Lynda [2 ]
机构：
[1] Univ Michigan, Susan B Meister Child Hlth Evaluat & Res CHEAR Ctr, Dept Pediat, Ann Arbor, MI USA
[2] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI USA
[3] Univ Michigan, Coll Pharm, Ann Arbor, MI USA
[4] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI USA
[5] Ohio State Univ, Nationwide Childrens Hosp, Ctr Innovat Pediat Practice, Sch Med, Columbus, OH USA
[6] 2800 Plymouth Rd,NCRC Bldg 16,Rm G027W, Ann Arbor, MI 48109 USA
来源：
PEDIATRIC BLOOD & CANCER | 2023年
关键词：
D O I：
10.1002/pbc.30630
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Hydroxyurea for the treatment of sickle cell anemia
    Platt, Orah S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (13): : 1362 - 1369
  • [42] Hydroxyurea therapy for sickle cell anemia
    McGann, Patrick T.
    Ware, Russell E.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2015, 14 (11) : 1749 - 1758
  • [43] Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents
    Reddy, Paavani S.
    Cai, Stephanie W.
    Barrera, Leonardo
    King, Kathryn
    Badawy, Sherif M.
    [J]. ANNALS OF MEDICINE, 2022, 54 (01) : 683 - 693
  • [44] Hydroxyurea Adherence and Associated Outcomes in Medicaid Enrollees with Sickle Cell Disease
    Candrilli, Sean D.
    O'Brien, Sarah
    Ware, Russell E.
    Balkrishnan, Rajesh
    [J]. BLOOD, 2009, 114 (22) : 979 - 980
  • [45] Clinical and laboratory effects of hydroxyurea in children and adolescents with sickle cell anemia:: A Portuguese hospital study
    Braga, LB
    Ferreira, AC
    Guimaraes, M
    Nazário, C
    Pacheco, P
    Miranda, A
    Picanço, I
    Seixas, T
    Rosado, L
    Amaral, JMV
    [J]. HEMOGLOBIN, 2005, 29 (03) : 171 - 180
  • [46] DEVELOPMENTAL CHANGES OF HYDROXYUREA PHARMACOKIN ETICS IN CHILDREN WITH SICKLE CELL ANEMIA
    Dong, M.
    Mizuno, T.
    Good, A.
    Hosawi, A.
    Vinks, A.
    Ware, R.
    McGann, P.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S90 - S90
  • [47] Hydroxyurea to Reduce Stroke Risk in Tanzanian Children with Sickle Cell Anemia
    Ambrose, Emmanuela E.
    Smart, Luke R.
    Songoro, Primrose
    Shabani, Idd
    Komba, Protas
    Charles, Mwesige
    Howard, Thad A.
    Stuber, Susan E.
    Lane, Adam
    Latham, Teresa
    Makubi, Abel Nkono
    Ware, Russell E.
    [J]. BLOOD, 2020, 136
  • [48] Spirometric Changes After Initiation of Hydroxyurea in Children With Sickle Cell Anemia
    Kotwal, Nidhi
    Pillai, Dinesh K.
    Darbari, Deepika S.
    Sun, Kai
    Koumbourlis, Anastassios C.
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2022, 44 (06) : E923 - E925
  • [49] Effect of Hydroxyurea Therapy on Pulmonary Function in Children with Sickle Cell Anemia
    McLaren, Anya
    Klingel, Michelle
    Behera, Suman
    Odame, Isaac
    Kirby-Allen, Melanie
    Grasemann, Hartmut
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195 (05) : 689 - 691
  • [50] Hydroxyurea in children with Sickle cell anemia, should it be a life long treatment?
    El Alfy, MS
    [J]. BLOOD, 2000, 96 (11) : 16B - 16B
12345